PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Free Cash Flow for the year ending December 31, 2023: USD -6.69 M

PainReform Ltd. Free Cash Flow is USD -6.69 M for the year ending December 31, 2023, a -3.45% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

PainReform Ltd. Free Cash Flow for the year ending December 31, 2022 was USD -6.46 M, a 2.09% change year over year.
PainReform Ltd. Free Cash Flow for the year ending December 31, 2021 was USD -6.60 M, a -157.23% change year over year.
PainReform Ltd. Free Cash Flow for the year ending December 31, 2020 was USD -2.57 M, a -321.51% change year over year.
PainReform Ltd. Free Cash Flow for the year ending December 31, 2019 was USD -609.00 K.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: PRFX

PainReform Ltd.

CEO	Dr. Ehud Geller Ph.D.
IPO Date	Sept. 1, 2020
Location	Israel
Headquarters	65 Yigal Alon Street
Employees	7
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Key trends

Past 5 years